期刊文献+

碳青霉烯类抗生素连续5年用药密度及细菌耐药性分析 被引量:20

Use Density of Carbapenems and Bacterial Drug Resistance in 5 Consecutive Years
原文传递
导出
摘要 目的:探讨碳青霉烯类抗生素用药密度变化对细菌耐药性所产生的影响。方法:对某院ICU病房碳青霉烯类抗生素的用药密度、相关致病菌的种类构成和耐药监测结果进行连续5年的年度分布汇总,分析对应时段的量变数据。结果:非发酵革兰阴性菌(NFGNB)对碳青霉烯类抗生素易产生耐药,且耐药率随用药密度的升降而波动。肠杆菌属细菌对碳青霉烯类的耐药率低,受用药密度的影响较小。结论:碳青霉烯类抗生素的用药密度与NFGNB耐药率的变化呈正相关。合理控制用药密度可使细菌耐药率减缓或下降。 OBJECTIVE: To investigate the effect of the correlation between the use density of carbapenems and the bacterial drug-resistance. METHODS: The data including the use density of carbapenems in the ICU ward of a hospital, the categories of the related pathogenic bacteria and monitoring results on drug resistances in 5 consecutive years were collected for an analysis of the quantitative change in a corresponding stage. RESULTS: Non - fermentative Gram - negative bacilli (NFGNB) were prone resistant to carbapenems and the resistant rate fluctuated in relation to the use density of carbapenems. The Enterobacter had low resistance to carbapenems and was independent of the use density of carbapenems. CONCLUSION: The use density of carbapenems has a positive correlation with the resistance of NFGNB. Reasonable drug use density may slow down or reduce bacterial drug - resistance.
出处 《中国药房》 CAS CSCD 北大核心 2008年第29期2267-2269,共3页 China Pharmacy
关键词 碳青霉烯类抗生素 用药密度 细菌耐药性 Carbapenems Drug use density Bacterial drug resistance
  • 相关文献

参考文献5

二级参考文献28

  • 1叶惠芬,陈惠玲,杨银梅,李红玉,苏丹虹,黄露霞.2003年广州地区常见病原菌耐药性调查[J].中国抗感染化疗杂志,2005,5(1):29-32. 被引量:39
  • 2朱德妹,汪复,张婴元.2004年上海地区细菌耐药性监测[J].中国抗感染化疗杂志,2005,5(4):195-200. 被引量:227
  • 3余娴,凌保东,雷军.某院产超广谱β-内酰胺酶临床分离革兰阴性杆菌的耐药性及基因型分析[J].中国药房,2007,18(1):25-27. 被引量:12
  • 4叶应妩,王毓三主编.全国临床检验操作规程[M].第1版.南京:东南大学出版社,1992:424~437.
  • 5Crouch B S, Wundesink R G, Joues C B, et al. Ventilatior-associated pneumonia due to Pseudomonas aeruginosa [J]. Chest, 1996,109(4): 1019
  • 6Arnow P M, Flaherty J P. Nonfermentative Gram-negative bacilli[A]. In: Mayhall CG, editor. Hospital epidemiology and infection control [M]. 2nd ed. Philadephia:Lippincott Williams and Wilkins, 1999: 959
  • 7Wunderink R G. Treatment of ventilator-associated pneumonia [A]. In: Wunderink RG, Rello J,editors.Ventilator-associated pneumonia[M]. Boston: Kluwer Academic Publisher, 2001: 89
  • 8Bartlett J G. Pocket book of infectious disease therapy[M]. Philadelphia: Lippincott Willams and Wilkins,2002: 19
  • 9Pena C,Pujol M,Ardanuy C,et al.Epidenmiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases[J].Antimicrob Agents Chemother,1998,42(1):53.
  • 10Lee N,Yuen KY,Kumana CR.Clinical role of betalactam/beta-lactamase inhibitor combinations[J].Drugs,2003,63(14):1 511.

共引文献67

同被引文献144

引证文献20

二级引证文献115

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部